ZyVersa Interest Expense vs Research Development Analysis

ZVSA Stock

1.14 0.01 0.87%

ZyVersa Therapeutics financial indicator trend analysis is more than just analyzing ZyVersa Therapeutics current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ZyVersa Therapeutics is a good investment. Please check the relationship between ZyVersa Therapeutics Interest Expense and its Research Development accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in ZyVersa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For information on how to trade ZyVersa Stock refer to our How to Trade ZyVersa Stock guide.

Interest Expense vs Research Development

Interest Expense vs Research Development Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ZyVersa Therapeutics Interest Expense account and Research Development. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between ZyVersa Therapeutics' Interest Expense and Research Development is -0.41. Overlapping area represents the amount of variation of Interest Expense that can explain the historical movement of Research Development in the same time period over historical financial statements of ZyVersa Therapeutics, assuming nothing else is changed. The correlation between historical values of ZyVersa Therapeutics' Interest Expense and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Interest Expense of ZyVersa Therapeutics are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Interest Expense i.e., ZyVersa Therapeutics' Interest Expense and Research Development go up and down completely randomly.

Correlation Coefficient

-0.41

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.

Research Development

Most indicators from ZyVersa Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ZyVersa Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in ZyVersa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For information on how to trade ZyVersa Stock refer to our How to Trade ZyVersa Stock guide.At present, ZyVersa Therapeutics' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Issuance Of Capital Stock is expected to grow to about 14.3 M, whereas Tax Provision is projected to grow to (8.4 M).

	2023	2024 (projected)
Interest Expense	457K	444.5K
Depreciation And Amortization	9.4K	8.3K

Interest Expense Depreciation And Amortization

ZyVersa Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Short Long Term Debt
Total Assets		-0.61	-0.7	0.14	0.99	0.73	-0.65	0.75	-0.63	-0.82	0.23	0.65	0.95	1.0	-0.87	-0.78	-0.26	0.95	-0.21	0.54	0.67	0.77	0.9	0.98	0.99	0.62
Short Long Term Debt Total	-0.61		0.55	0.22	-0.59	-0.79	0.12	-0.22	0.33	0.95	0.28	-0.77	-0.7	-0.6	0.73	0.76	0.59	-0.7	-0.33	0.31	0.0	-0.74	-0.34	-0.53	-0.58	-0.26
Other Current Liab	-0.7	0.55		-0.66	-0.63	-0.95	0.87	-0.09	0.97	0.74	0.48	-0.89	-0.85	-0.69	0.93	0.96	0.72	-0.85	-0.45	-0.38	-0.73	-0.94	-0.81	-0.62	-0.66	-0.92
Total Current Liabilities	0.14	0.22	-0.66		0.06	0.42	-0.84	-0.3	-0.8	0.01	-0.5	0.33	0.26	0.13	-0.38	-0.43	-0.48	0.26	0.35	0.54	0.77	0.38	0.54	0.08	0.12	0.77
Total Stockholder Equity	0.99	-0.59	-0.63	0.06		0.66	-0.58	0.82	-0.56	-0.79	0.32	0.62	0.93	0.99	-0.83	-0.72	-0.13	0.93	-0.24	0.55	0.61	0.74	0.85	1.0	0.98	0.58
Other Liab	0.73	-0.79	-0.95	0.42	0.66		-0.69	0.11	-0.84	-0.9	-0.49	0.93	0.88	0.72	-0.95	-1.0	-0.79	0.88	0.46	0.14	0.54	0.96	0.72	0.63	0.69	0.76
Net Tangible Assets	-0.65	0.12	0.87	-0.84	-0.58	-0.69		-0.2	0.95	0.41	0.22	-0.59	-0.71	-0.64	0.75	0.73	0.46	-0.71	-0.14	-0.74	-0.96	-0.7	-0.9	-0.6	-0.63	-0.93
Property Plant And Equipment Net	0.75	-0.22	-0.09	-0.3	0.82	0.11	-0.2		-0.07	-0.39	0.81	0.11	0.56	0.76	-0.37	-0.19	0.42	0.56	-0.67	0.57	0.35	0.24	0.55	0.84	0.77	0.14
Current Deferred Revenue	-0.63	0.33	0.97	-0.8	-0.56	-0.84	0.95	-0.07		0.57	0.43	-0.8	-0.77	-0.62	0.85	0.86	0.61	-0.77	-0.41	-0.54	-0.83	-0.85	-0.82	-0.56	-0.58	-0.98
Net Debt	-0.82	0.95	0.74	0.01	-0.79	-0.9	0.41	-0.39	0.57		0.2	-0.86	-0.9	-0.81	0.9	0.9	0.58	-0.9	-0.25	-0.01	-0.31	-0.89	-0.62	-0.75	-0.78	-0.52
Retained Earnings	0.23	0.28	0.48	-0.5	0.32	-0.49	0.22	0.81	0.43	0.2		-0.48	-0.03	0.25	0.25	0.42	0.82	-0.03	-0.89	0.43	0.01	-0.37	0.07	0.36	0.28	-0.34
Accounts Payable	0.65	-0.77	-0.89	0.33	0.62	0.93	-0.59	0.11	-0.8	-0.86	-0.48		0.84	0.63	-0.93	-0.94	-0.63	0.84	0.61	0.09	0.39	0.98	0.58	0.59	0.57	0.79
Cash	0.95	-0.7	-0.85	0.26	0.93	0.88	-0.71	0.56	-0.77	-0.9	-0.03	0.84		0.95	-0.98	-0.92	-0.43	1.0	0.09	0.45	0.65	0.93	0.87	0.92	0.92	0.76
Non Current Assets Total	1.0	-0.6	-0.69	0.13	0.99	0.72	-0.64	0.76	-0.62	-0.81	0.25	0.63	0.95		-0.86	-0.77	-0.24	0.95	-0.22	0.55	0.67	0.76	0.9	0.99	1.0	0.61
Non Currrent Assets Other	-0.87	0.73	0.93	-0.38	-0.83	-0.95	0.75	-0.37	0.85	0.9	0.25	-0.93	-0.98	-0.86		0.98	0.57	-0.98	-0.3	-0.36	-0.63	-0.98	-0.82	-0.81	-0.82	-0.83
Other Assets	-0.78	0.76	0.96	-0.43	-0.72	-1.0	0.73	-0.19	0.86	0.9	0.42	-0.94	-0.92	-0.77	0.98		0.74	-0.92	-0.4	-0.23	-0.6	-0.97	-0.77	-0.69	-0.74	-0.8
Long Term Debt	-0.26	0.59	0.72	-0.48	-0.13	-0.79	0.46	0.42	0.61	0.58	0.82	-0.63	-0.43	-0.24	0.57	0.74		-0.43	-0.59	0.23	-0.31	-0.61	-0.37	-0.09	-0.24	-0.45
Cash And Short Term Investments	0.95	-0.7	-0.85	0.26	0.93	0.88	-0.71	0.56	-0.77	-0.9	-0.03	0.84	1.0	0.95	-0.98	-0.92	-0.43		0.09	0.45	0.65	0.93	0.87	0.92	0.92	0.76
Common Stock Shares Outstanding	-0.21	-0.33	-0.45	0.35	-0.24	0.46	-0.14	-0.67	-0.41	-0.25	-0.89	0.61	0.09	-0.22	-0.3	-0.4	-0.59	0.09		-0.42	-0.14	0.46	-0.16	-0.28	-0.29	0.4
Non Current Liabilities Total	0.54	0.31	-0.38	0.54	0.55	0.14	-0.74	0.57	-0.54	-0.01	0.43	0.09	0.45	0.55	-0.36	-0.23	0.23	0.45	-0.42		0.85	0.25	0.74	0.6	0.55	0.61
Other Current Assets	0.67	0.0	-0.73	0.77	0.61	0.54	-0.96	0.35	-0.83	-0.31	0.01	0.39	0.65	0.67	-0.63	-0.6	-0.31	0.65	-0.14	0.85		0.54	0.93	0.64	0.68	0.8
Other Stockholder Equity	0.77	-0.74	-0.94	0.38	0.74	0.96	-0.7	0.24	-0.85	-0.89	-0.37	0.98	0.93	0.76	-0.98	-0.97	-0.61	0.93	0.46	0.25	0.54		0.72	0.71	0.71	0.84
Total Liab	0.9	-0.34	-0.81	0.54	0.85	0.72	-0.9	0.55	-0.82	-0.62	0.07	0.58	0.87	0.9	-0.82	-0.77	-0.37	0.87	-0.16	0.74	0.93	0.72		0.86	0.9	0.79
Net Invested Capital	0.98	-0.53	-0.62	0.08	1.0	0.63	-0.6	0.84	-0.56	-0.75	0.36	0.59	0.92	0.99	-0.81	-0.69	-0.09	0.92	-0.28	0.6	0.64	0.71	0.86		0.98	0.59
Property Plant And Equipment Gross	0.99	-0.58	-0.66	0.12	0.98	0.69	-0.63	0.77	-0.58	-0.78	0.28	0.57	0.92	1.0	-0.82	-0.74	-0.24	0.92	-0.29	0.55	0.68	0.71	0.9	0.98		0.56
Short Long Term Debt	0.62	-0.26	-0.92	0.77	0.58	0.76	-0.93	0.14	-0.98	-0.52	-0.34	0.79	0.76	0.61	-0.83	-0.8	-0.45	0.76	0.4	0.61	0.8	0.84	0.79	0.59	0.56

Click cells to compare fundamentals

ZyVersa Therapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GOOG	Alphabet Inc Class C
CRM	Salesforce

When determining whether ZyVersa Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ZyVersa Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zyversa Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zyversa Therapeutics Stock:

How To Invest In ZyVersa

Details

Is ZyVersa Stock a good investment?

Details

What is ZyVersa Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in ZyVersa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For information on how to trade ZyVersa Stock refer to our How to Trade ZyVersa Stock guide.

You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ZyVersa Therapeutics. If investors know ZyVersa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ZyVersa Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

491.97

Return On Assets

(0.25)

Return On Equity

(1.52)

The market value of ZyVersa Therapeutics is measured differently than its book value, which is the value of ZyVersa that is recorded on the company's balance sheet. Investors also form their own opinion of ZyVersa Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is ZyVersa Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ZyVersa Therapeutics' market value can be influenced by many factors that don't directly affect ZyVersa Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between ZyVersa Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ZyVersa Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ZyVersa Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ZyVersa Interest Expense vs Research Development Analysis

Interest Expense vs Research Development

Interest Expense vs Research Development Correlation Analysis

Correlation Coefficient

Interest Expense

Research Development

ZyVersa Therapeutics fundamental ratios Correlations

ZyVersa Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Cash And Short Term Investments	+ 1.0	Cash
Property Plant And Equipment Gross	+ 1.0	Non Current Assets Total
Total Stockholder Equity	+ 0.99	Total Assets
Property Plant And Equipment Gross	+ 0.99	Total Assets

Other Assets	- 1.0	Other Liab
Other Stockholder Equity	- 0.98	Non Currrent Assets Other
Cash And Short Term Investments	- 0.98	Non Currrent Assets Other
Non Currrent Assets Other	- 0.98	Cash
Short Long Term Debt	- 0.98	Current Deferred Revenue
Other Stockholder Equity	- 0.97	Other Assets